The results of the survey among the parents of patients with achondroplasia on the role of vosoritide therapy
https://doi.org/10.18019/1028-4427-2021-27-4-487-492
Abstract
Introduction. Achondroplasia (ACP) is a common skeletal dysplasia. Vozoritide is the first drug that has an effect on the pathogenesis of impaired enchondral growth in achondroplasia. Clinical trials of the second and third phases have shown its effectiveness according to the latest literature data presented. After providing scientifically grounded information, a questionnaire was completed by parents of children with ACP to have their opinion before the introduction of the drug into medical practice.
Materials and methods. The survey was conducted on June 21-24, 2021 at the Ilizarov Center supported by the patient’s organization Small People Support Center for Patients with Achondroplasia and Other Bone Dysplasias and Their Families. The questionnaire included 5 questions, compiled by the first author of this study. 65 completed questionnaires were received for the analysis.
Results and discussion. The overwhelming majority of parents have confidence in the use of vozoritide as a means of achieving targeted growth which may allow to avoid surgical treatment. However, the parallel use of this drug and surgical treatment for incomplete growth of a child is not excluded if the growth graphs show that the required parameters have not been achieved by the time the growth zones are closed. Despite the fact that at present only the influence of vozoritide on the growth of a child with ACP has been reliably proven, parents feel confident with the information about the possible effect of the drug on other problems associated with impaired enchondral growth, and are ready to start therapy at an earlier age and for a longer period. Parents do not oppose the pharmacological treatment to surgical treatment. Vozoritide is seen as the main component of treatment, and surgery as a complementary one that follows (if necessary). This reasonable combination increases the parents' confidence in the predicted favorable treatment outcome.
About the Authors
D. A. Popkov
Ilizarov National Medical Research Centre for Traumatology and Orthopedics
Russian Federation
Russian Federation
Dmitry A. Popkov, M.D., Ph.D., Professor of RAS, correspondent member French Academy of Medical Sciences,
Kurgan
Ju. V. Nesterova
Russian Association of Dwarfism
Russian Federation
Russian Federation
Julia V. Nesterova,
Moscow
A. M. Aranovich
Ilizarov National Medical Research Centre for Traumatology and Orthopedics
Russian Federation
Russian Federation
Anna M. Aranovich, M.D., Ph.D., Professor,
Kurgan
References
1. Martínez-Frías ML., Bermejo E., Cereijo A., Sánchez M., López M., Gonzalo C. Epidemiological aspects of Mendelian syndromes in a Spanish population sample: II. Autosomal recessive malformation syndromes. Am. J. Med. Genet., 1991, vol. 38, no. 4, pp. 626-629. DOI: 10.1002/ajmg.1320380425.
2. Oberklaid F., Danks D.M., Jensen F., Stace L., Rosshandler S. Achondroplasia and hypochondroplasia: Comments on frequency, mutation rate, and radiological features in skull and spine. J. Med. Genet., 1979, vol.16, no. 2, pp. 140-146. DOI: 10.1136/jmg.16.2.140.
3. Waller D.K., Correa A., Vo T.M., Wang Y., Hobbs C., Langlois P.H., Pearson K., Romitti P.A., Shaw G.M., Hecht J.T. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am. J. Med. Genet. A, 2008, vol. 146A, no. 18, pp. 2385- 2389. DOI: 10.1002/ajmg.a.32485.
4. Gardner R.J. A new estimate of the achondroplasia mutation rate. Clin. Genet., 1977, vol. 11, no. 1, pp. 31-38. DOI: 10.1111/j.1399-0004.1977.tb01274.x.
5. Orioli I.M., Castilla E.E., Barbosa-Neto J.G. The birth prevalence rates for the skeletal dysplasias. J. Med. Genet., 1986, vol. 23, no. 4, pp. 328-332. DOI: 10.1136/jmg.23.4.328.
6. Foldynova-Trantirkova S., Wilcox W.R., Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat., 2012, vol. 33, no. 1, pp. 29-41. DOI: 10.1002/humu.21636.
7. Richette P., Bardin T., Stheneur C. Achondroplasia: from genotype to phenotype. Joint Bone Spine, 2008, vol.75, no. 2, pp. 125-130. DOI: 10.1016/j.jbspin.2007.06.007.
8. Wright M.J., Irving M.D. Clinical management of achondroplasia. Arch. Dis. Child., 2012, vol. 97, no. 2, pp. 129-134. DOI: 10.1136/adc.2010.189092.
9. Horton W.A., Hall J.G., Hecht J.T. Achondroplasia. Lancet, 2007, vol. 370, no. 9582, pp. 162-172. DOI: 10.1016/S0140-6736(07)61090-3.
10. Hunter A.G., Bankier A., Rogers J.G., Sillence D., Scott C.I. Jr. Medical complications of achondroplasia: a multicentre patient review. J. Med. Genet., 1998, vol. 35, no. 9, pp. 705-712. DOI: 10.1136/jmg.35.9.705.
11. Mahomed N.N., Spellmann M., Goldberg M.J. Functional health status of adults with achondroplasia. Am. J. Med. Genet., 1998, vol. 78, no. 1, pp. 30-35. DOI: 10.1002/(sici)1096-8628(19980616)78:13.0.co;2-p.
12. Ireland P.J., Johnson S., Donaghey S., Johnston L., McGill J., Zankl A., Ware R.S., Pacey V., Ault J., Savarirayan R., Sillence D., Thompson E., Townshend S. Developmental milestones in infants and young Australasian children with achondroplasia. J. Dev. Behav. Pediatr., 2010, vol. 31, no. 1, pp. 41-47. DOI: 10.1097/DBP.0b013e3181c72052.
13. Alade Y., Tunkel D., Schulze K., McGready J., Jallo G., Ain M., Yost T., Hoover-Fong J. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin. Genet., 2013, vol. 84, no. 3, pp. 237-243. DOI: 10.1111/cge.12045.
14. Hecht J.T., Francomano C.A., Horton W.A., Annegers J.F. Mortality in achondroplasia. Am. J. Hum. Genet., 1987, vol. 41, no. 3, pp. 454-464.
15. Miccoli M., Bertelloni S., Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm. Res. Paediatr., 2016, vol. 86, no. 1, pp. 27-34. DOI: 10.1159/000446958.
16. Harada D., Namba N., Hanioka Y., Ueyama K., Sakamoto N., Nakano Y., Izui M., Nagamatsu Y., Kashiwagi H., Yamamuro M., Ishiura Y., Ogitani A., Seino Y. Final adult height in long-term growth hormone-treated achondroplasia patients. Eur. J. Pediatr., 2017, vol. 176, no. 7, pp. 873-879. DOI: 10.1007/s00431-017-2923-y.
17. Popkov A.V., Shevtsov V.I., editors. Akhondroplaziia: rukovodstvo dlia vrachei [Achondroplasia: a guide for physicians]. M., Meditsina, 2001, 352 p. (in Russian)
18. Shchukin A.A., Aranovich A.M., Popkov A.V., Popkov D.A. Otsenka rezultatov udlineniia nizhnikh konechnostei u patsientov s sistemnymi zabolevaniiami skeleta, soprovozhdaiushchimisia patologicheski nizkim rostom [Evaluation of the results of lower limb lengthening in patients with systemic skeletal diseases accompanied by pathologically short stature]. Genij Ortopedii, 2014, no. 2, pp. 44-51. (in Russian)
19. Menshchikova T.I., Aranovich A.M. Udlinenie golenei u bolnykh akhondroplaziei 6-9 let kak pervyi etap korrektsii rosta [Tibial lengthening in achondroplasia patients aged 6–9 years as the first stage of growth correction]. Genij Ortopedii, 2021, vol. 27, no. 3, pp. 366-371. DOI10.18019/1028-4427-2021-27-3-366-371.
20. Wendt D.J., Dvorak-Ewell M., Bullens S., Lorget F., Bell S.M., Peng J., Castillo S., Aoyagi-Scharber M., O'Neill C.A., Krejci P., Wilcox W.R., Rimoin D.L., Bunting S. Neutral endopeptidase-resistant C type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J. Pharmacol. Exp. Ther., 2015, vol. 353, no. 1, pp. 132-149. DOI: 10.1124/jpet.114.218560.
21. Lorget F., Kaci N., Peng J., Benoist-Lasselin C., Mugniery E., Oppeneer T., Wendt D.J., Bell S.M., Bullens S., Bunting S., Tsuruda L.S., O'Neill C.A., Di Rocco F., Munnich A., Legeai-Mallet L. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet., 2012, vol. 91, no. 6, pp. 1108-1114. DOI: 10.1016/j.ajhg.2012.10.014.
22. Savarirayan R., Irving M., Bacino C.A., Bostwick B., Charrow J., Cormier-Daire V., Le Quan Sang K.H., Dickson P., Harmatz P., Phillips J., Owen N., Cherukuri A., Jayaram K., Jeha G.S., Larimore K., Chan M.L., Huntsman Labed A., Day J., Hoover-Fong J. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med., 2019, vol. 381, no. 1, pp. 25-35. DOI: 10.1056/NEJMoa1813446.
23. Savarirayan R., Tofts L., Irving M., Wilcox W., Bacino C.A., Hoover-Fong J., Ullot Font R., Harmatz P., Rutsch F., Bober M.B., Polgreen L.E., Ginebreda I., Mohnike K., Charrow J., Hoernschemeyer D., Ozono K., Alanay Y., Arundel P., Kagami S., Yasui N., White K.K., Saal H.M., LeivaGea A., Luna-González F., Mochizuki H., Basel D., Porco D.M., Jayaram K., Fisheleva E., Huntsman-Labed A., Day J. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet, 2020, vol. 396, no. 10252, pp. 684-692. DOI: 10.1016/S0140-6736(20)31541-5.
Review
For citations:
Popkov D.A., Nesterova J.V., Aranovich A.M. The results of the survey among the parents of patients with achondroplasia on the role of vosoritide therapy. Genij Ortopedii. 2021;27(4):487-492. https://doi.org/10.18019/1028-4427-2021-27-4-487-492
Views:
273
Email this article 